Printer Friendly

RECEPTAGEN SPONSORS RESEARCH WITH STATE UNIVERSITY OF NEW YORK HEALTH SCIENCE CENTER

 SEATTLE, Sept. 9 /PRNewswire/ -- Receptagen Corp. (formerly Vita- Med Inc.), a Seattle-based biotechnology company and subsidiary of the public Canadian company, Receptagen Ltd. (Alberta: RCG), today signed a multi-year research agreement with the State University of New York (SUNY) Health Science Center at Brooklyn to isolate and clone the cell receptor involved in vitamin-B12 uptake. The research is part of Receptagen's program to develop "growth blocker" drugs that inhibit the proliferation of cancer cells. Financial details were not disclosed.
 "We are pleased to work with a leading laboratory in vitamin-B12 research and to explore commercial opportunities based on their years of research in this area," said A. Charles Morgan, Ph.D., president and chief technical officer of Receptagen Corp.
 SUNY associate professor Edward V. Quadros, Ph.D., and Sheldon Rothenberg, M.D., professor of medicine and chief of hematology and oncology, also at SUNY, have been researching various aspects of vitamin- B12 metabolism for the past 20 years. The investigators will be collaborating with Receptagen scientists and researchers at the University of Washington and The Biomedical Research Centre at the University of British Columbia.
 "Our agreement represents the third key component of Receptagen's research network, providing us with the necessary technical expertise to create several forms of growth blockers," said Morgan. "It will enhance our proprietary position by allowing us to produce a pipeline of products, ranging from small molecules to protein and antibody-based drugs selected for different clinical indications."
 Growth Blockers
 Receptagen is developing "growth blocker" drugs aimed at regulating the uptake of vitamin B12 and blocking uncontrolled cell growth. Work is already underway to isolate and clone the receptor necessary for the uptake of vitamin B12 by cells. The gene sequences discovered can be used to explore antisense and receptor-based inhibitors of vitamin-B12 uptake. Prior studies have shown that cells die if vitamin-B12 metabolism is blocked. If this approach can be selective for cancer cells, it could have potential therapeutic benefit.
 Founded in 1992, Receptagen Corp. is engaged in developing proprietary growth-blocker drugs for the treatment of cancer and other life-threatening diseases marked by uncontrolled cell proliferation. The company is focusing on AIDS-related lymphoma, a malignant cancer of the lymphatic system that is projected to increase dramatically over the next decade.
 -0- 8/9/93
 /CONTACT: In the United States: Warren Wheeler, vice president, Business Development of Receptagen, 206-778-5260; or Charles Versaggi of Gable/Versaggi Biocommunications, 408-358-4162, for Receptagen; or, in Canada: Doug Ford or Gail Thurston, both of Enterprise Development Corp., 604-685-0114/
 (RCG)


CO: Receptagen Corp. ST: Washington IN: MTC SU:

TB-TM -- SJ001 -- 0120 09/09/93 08:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1993
Words:433
Previous Article:ALL WEEK LONG BY EDDIE BAUER AND READING IS FUNDAMENTAL TEAM UP TO PROMOTE CHILDREN'S LITERACY
Next Article:NDC ANNOUNCES ELECTRONIC TAX FILING SERVICE FOR STATE REVENUE AGENCIES AND CORPORATIONS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters